期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

恶性肿瘤患者血清中PKM2水平的诊断和预后预测价值 被引量：3

The Diagnostic and Prognostic Value of Serum PKM2 in Patients with Cancer
原文传递
导出
摘要 PKM2作为有氧糖酵解关键酶,与肿瘤发生发展密切相关,在其诊断、预后及治疗方面均有很好的临床应用价值。恶性肿瘤患者血清中PKM2的浓度显著高于非恶性肿瘤患者及正常人,但在不同亚型的泌尿系统肿瘤中PKM2的诊断价值不同;PKM2与传统肿瘤标志物联合时,能显著提高诊断的灵敏度和特异性;PKM2浓度的上升与OS和PFS降低相关;治疗有效时PKM2浓度随之下降。另外,基础研究提示PKM2是重要的治疗靶点。 As a key enzyme of aerobic glycolysis,PKM2 closely relates to the generation and development of tumor,which has a crucial value of diagnosis,prognosis and treatment in clinical. In the aspect of diagnose,the density of serum PKM2 in cancer patients is significantly higher than that in nonmalignant disease patients,while the diagnostic value is different in various subtype of urogenital neoplasms; when associate with traditional tumor markers,PKM2 shows an increasing sensitivity and specific ability of diagnosis. In the aspect of prognosis,the ascending of the PKM2 density is accompanied with the descending of OS and PFS; the density of PKM2 will descend while the treatment is effective. In the aspect of treatment,there are several studies prompt that PKM2 is an important target for treatment.
作者 尹晨希 周菲菲 夏良平
机构地区 华南肿瘤学国家重点实验室 中山大学肿瘤防治中心 佛山市第一人民医院
出处 《肿瘤学杂志》 CAS 2013年第7期565-569,共5页 Journal of Chinese Oncology
基金 国家自然科学基金项目(81272641)
关键词 PKM2 肿瘤 诊断 预后 血清 PKM2 neoplasms diagnosis prognosis serum
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献45

  • 1Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D.Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.Anticancer Res 2000; 20:5095-5098.
  • 2Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K,Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26.
  • 3Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loenng SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urology A 2000; 39:554-556.
  • 4Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA,CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.Anticancer Res 2000; 20:5053-5058.
  • 5Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G,Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318.
  • 6Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res 2003: 23(2A): 899-906.
  • 7Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG,Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003;2:185-191.
  • 8Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20:5029-5033.
  • 9Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE,Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
  • 10Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ,Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187:223-228.

共引文献29

同被引文献21

  • 1Komaki R,Tsao AS,Mehran RJ.Non-Small Cell Lung Cancer[M].Springer New York,2013:45-62.
  • 2Bradley JD,Paulus R,Komaki R,et al.A randomized phase III comparison of standard-dose(60 Gy)versus high-dose(74 Gy)conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer:Results on radiation dose in RTOG 0617[J].J Clin Oncol,2013,31(15):7501.
  • 3Wang XC,Du LQ,Tian LL,et al.Expression and function of mi RNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer[J].Lung Cancer,2011,72(1):92-99.
  • 4Martinez-Balibrea E,Plasencia C,Ginés A,et al.A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines[J].Molecular Cancer Therapeutics,2009,8(4):771-778.
  • 5Shi HS,Li D,Zhang HL,et al.Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice[J].Cancer Science,2010,101(6):1447-1453.
  • 6Papadaki C,Sfakianaki M,Lagoudaki E,et al.PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer[J].Br J Cancer,2014,111(9):1757-1764.
  • 7Chaneton B,Gottlieb E."Rocking cell metabolism:revised functions of the key glycolytic regulator PKM2 in cancer[J].Trends Biochemi Sci,2012,37(8):309-316.
  • 8Mazurek S,Boschek CB,Hugo F,et al.Pyruvate kinase type M2and its role in tumor growth and spreading[J].Semina Cancer Biol,2005,15(4):300-308.
  • 9崔爽爽.Micro RNA表达与非小细胞肺癌放疗敏感性关系的研究[J].中国协和医科大学学报,2013,19(7):565-569.
  • 10Yang W,Xia Y,Can Y,et al.EGFR-Induced and PKC Monoubiquitylation-Dependent NF-B Activation Upregulates PKM2Expression and Promotes Tumorigenesis[J].Molecular Cell,2012,48(5):771-784.

引证文献3

二级引证文献14

肿瘤学杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部